Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, open label, two-stage, two-part, two-sequence, two-way crossover study in normal healthy adult volunteers to assess the bioequivalence of two formulations of darbepoetin alfa administered by two different routes of administration

Next Previous
X
Search
Trial Profile

A randomized, open label, two-stage, two-part, two-sequence, two-way crossover study in normal healthy adult volunteers to assess the bioequivalence of two formulations of darbepoetin alfa administered by two different routes of administration

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darbepoetin alfa (Primary)
  • Indications Anaemia
  • Focus Pharmacokinetics
  • Sponsors Dr Reddys Laboratories

    • Most Recent Events

    • 07 Sep 2016 New trial record
    • 16 Aug 2016 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top